BackAstrazeneca plc Overview

Astrazeneca plc Other Current Liabilities

Astrazeneca plc's other current liabilities is $770M.

Get informed when a big investor buys or sells

+ Follow
Other Current Liabilities
$767.00M
48.87% YoYΔ $-733.00M vs prior year quarter

Peer average / median

Loading

Astrazeneca plc Other Current Liabilities History

Loading

Astrazeneca plc vs. peers: Other Current Liabilities Comparison

Loading

Astrazeneca plc Other Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Astrazeneca plc (AZN) FAQ

Astrazeneca plc posts a other current liabilities of $770M as of December 2025. That compares with $1.5B in the prior-year period — down 48.9% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Astrazeneca plc's other current liabilities was $1.5B. The latest reading is $770M — a 48.9% year-over-year decrease (period ending December 2025). Use the history and growth charts on this page for a longer lookback.

Other Current Liabilities is one piece of Astrazeneca plc's financial statement story. At $770M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for AZN's other current liabilities usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Astrazeneca plc's other metric pages and overview cover the third.

Judging Astrazeneca plc against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in other current liabilities easier to interpret. Start with $770M here, then scan peer and history charts to see if the gap is persistent.